Quebec Public Insurance Declines to Cover Wegovy, Citing Cost

Quebec's public prescription drug insurance plan will not cover Wegovy, with the province's health research institute citing high costs and uncertain benefits as the basis for the decision [Source: ctvnews.ca/montreal/article/quebec-public-insurance-wont-cover-wegovy-due-to-high-cost-uncertain-benefits/].

What Quebec Decided

CTV News reported on April 20, 2026 that Quebec's health research institute concluded Wegovy's costs are too high and the benefits uncertain, leading the province's public insurance plan to decline coverage of the Novo Nordisk semaglutide pen [Source: ctvnews.ca/montreal/article/quebec-public-insurance-wont-cover-wegovy-due-to-high-cost-uncertain-benefits/]. The decision means Quebec residents who rely on the public drug plan will not have the product reimbursed under the provincial formulary.

Consistent With a Broader Canadian Pattern

Quebec's stance aligns with the status of Wegovy across the country. As of January 2026, no Canadian provincial health plan provides coverage for Wegovy when it is prescribed for weight management [Source: ogaei.ca/blog/wegovy-cost-in-canada/]. Provincial programs including Ontario's Ontario Drug Benefit, British Columbia's PharmaCare and Quebec's public prescription drug insurance plan reimburse GLP-1 medications only for Type 2 diabetes management, not for weight management [Source: ogaei.ca/blog/wegovy-cost-in-canada/].

Failed Price Negotiations Preceded the Decision

Quebec's refusal follows a national-level impasse on Wegovy pricing. The Canadian Drug Agency assessed Wegovy's cost-effectiveness in July 2025 and recommended a price reduction before public coverage could be justified [Source: ogaei.ca/blog/wegovy-cost-in-canada/]. In December 2025, negotiations between the pan-Canadian Pharmaceutical Alliance and Novo Nordisk concluded without an agreement, with the manufacturer declining to negotiate on price [Source: ogaei.ca/blog/wegovy-cost-in-canada/].

What Wegovy Costs Patients Paying Out of Pocket

Without insurance coverage, a single Wegovy pen typically costs between $400 and $570 CAD per month in Canada, with annual out-of-pocket costs reaching approximately $5,066 CAD at the maintenance dose [Source: ogaei.ca/blog/wegovy-cost-in-canada/]. Current pharmacy prices tracked on GLP1Prices.ca range from $270 to $599 CAD per month, broadly consistent with that retail band.

Private insurance coverage remains limited. Fewer than 10% of Canadians currently have private insurance coverage for weight loss medications, and while approximately 31% of Canadian employers now include GLP-1 medication coverage in their benefit plans, 56% of employers who do offer coverage restrict it to diabetes management only [Source: ogaei.ca/blog/wegovy-cost-in-canada/]. Patients can review their options using our insurance coverage checker.

Wegovy's Regulatory Profile in Canada

Wegovy is the version of semaglutide approved by Health Canada for weight management, while Ozempic is officially approved only for people with Type 2 diabetes [Source: walkin.ca/blog/wegovy-canada/]. Wegovy is also approved in Canada for cardiovascular risk reduction in people with established heart disease, and as a standalone treatment for the liver condition MASH [Source: walkin.ca/blog/wegovy-canada/]. It is delivered using a multi-dose FlexTouch pen that contains a four-week supply [Source: walkin.ca/blog/wegovy-canada/].

Context Ahead of Generic Entry

Quebec's decision arrives as Canada's semaglutide market prepares for generic competition. The cost calculus for public plans could shift if lower-priced generic versions reach Canadian pharmacy shelves later this year. Patients tracking timing for those approvals can follow our generic semaglutide tracker, and can review how Wegovy compares with tirzepatide options such as Mounjaro and Zepbound, or the oral semaglutide tablet Rybelsus. Additional questions about coverage and pricing are addressed in our FAQ.

This article is for informational purposes only and does not constitute medical advice.